|
|
Volumn 125, Issue 3, 2013, Pages 7-20
|
|
Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes.
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ADAMANTANE;
ANTIDIABETIC AGENT;
DIPEPTIDYL PEPTIDASE IV INHIBITOR;
DRUG DERIVATIVE;
LIPID;
NITRILE;
PYRAZINE DERIVATIVE;
PYRROLIDINE DERIVATIVE;
SITAGLIPTIN;
TRIAZOLE DERIVATIVE;
VILDAGLIPTIN;
BLOOD;
BLOOD PRESSURE;
BODY WEIGHT;
CARDIOVASCULAR SYSTEM;
CHEMICALLY INDUCED DISORDER;
CORONARY ARTERY DISEASE;
DRUG EFFECT;
GLUCOSE BLOOD LEVEL;
HUMAN;
NON INSULIN DEPENDENT DIABETES MELLITUS;
REVIEW;
RISK FACTOR;
ADAMANTANE;
BLOOD GLUCOSE;
BLOOD PRESSURE;
BODY WEIGHT;
CARDIOVASCULAR SYSTEM;
CORONARY ARTERY DISEASE;
DIABETES MELLITUS, TYPE 2;
DIPEPTIDYL-PEPTIDASE IV INHIBITORS;
HUMANS;
HYPOGLYCEMIC AGENTS;
LIPIDS;
NITRILES;
PYRAZINES;
PYRROLIDINES;
RISK FACTORS;
TRIAZOLES;
|
|
EID: 84882282651
PISSN: None
EISSN: 19419260
Source Type: None
DOI: 10.3810/pgm.2013.05.2659 Document Type: Review |
|
Times cited : (80)
|
|
References (0)
|
